Idiopathic Pulmonary Fibrosis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Idiopathic Pulmonary Fibrosis – Pipeline Review, H2 2016’, provides an overview of the Idiopathic Pulmonary Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis

The report reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Idiopathic Pulmonary Fibrosis therapeutics and enlists all their major and minor projects

The report assesses Idiopathic Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AdAlta Pty Ltd.

Aeolus Pharmaceuticals, Inc.

Afferent Pharmaceuticals, Inc.

Apellis Pharmaceuticals Inc

ARMO Biosciences, Inc.

Asahi Kasei Pharma Corp.

Biogen Inc

Bioneer Corporation

BiOrion Technologies B.V.

Bristol-Myers Squibb Company

Celgene Corporation

Chrysalis Pharma SAS

Compugen Ltd.

Cynata Therapeutics Limited

F. Hoffmann-La Roche Ltd.

FibroGen, Inc.

FibroStatin SL

Galapagos NV

GenKyoTex S.A.

GlaxoSmithKline Plc

Global Blood Therapeutics, Inc.

GNI Group Ltd.

HEC Pharm Co., Ltd.

Histocell S.L.

iBio, Inc.

Immunomet Therapeutics, Inc.

Inventiva

Isarna Therapeutics GmbH

Kadmon Corporation, LLC

Kasiak Research Private Limited

Kolltan Pharmaceuticals, Inc.

Kyorin Pharmaceutical Co., Ltd.

Lung Therapeutics Inc

Moerae Matrix, Inc.

MorphoSys AG

Novartis AG

Nuevolution AB

Pharmaxis Limited

Promedior, Inc.

ProMetic Life Sciences Inc.

Pulmatrix, Inc.

Respira Therapeutics Inc

Ribomic Inc.

Saje Pharma, LLC

Samumed LLC

Sanofi

Sorrento Therapeutics, Inc.

SPR Biosciences LLC

Teva Pharmaceutical Industries Ltd.

Therabron Therapeutics, Inc.

Vicore Pharma AB

Yuhan Corporation

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Idiopathic Pulmonary Fibrosis Overview 7

Therapeutics Development 8

Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies 10

Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 14

Idiopathic Pulmonary Fibrosis - Pipeline Products Glance 15

Idiopathic Pulmonary Fibrosis - Products under Development by Companies 18

Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 23

Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development 24

Idiopathic Pulmonary Fibrosis - Therapeutics Assessment 76

Drug Profiles 89

Idiopathic Pulmonary Fibrosis - Dormant Projects 237

Idiopathic Pulmonary Fibrosis - Discontinued Products 241

Idiopathic Pulmonary Fibrosis - Product Development Milestones 242

Appendix 249

List of Tables

List of Tables

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2016 18

Number of Products under Development for Idiopathic Pulmonary Fibrosis – Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Development by Companies, H2 2016 (Contd..1) 21

Number of Products under Development by Companies, H2 2016 (Contd..2) 22

Number of Products under Development by Companies, H2 2016 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Comparative Analysis by Late Stage Development, H2 2016 25

Comparative Analysis by Clinical Stage Development, H2 2016 26

Comparative Analysis by Early Stage Development, H2 2016 27

Products under Development by Companies, H2 2016 28

Products under Development by Companies, H2 2016 (Contd..1) 29

Products under Development by Companies, H2 2016 (Contd..2) 30

Products under Development by Companies, H2 2016 (Contd..3) 31

Products under Development by Companies, H2 2016 (Contd..4) 32

Products under Investigation by Universities/Institutes, H2 2016 33

Idiopathic Pulmonary Fibrosis – Pipeline by AdAlta Pty Ltd., H2 2016 34

Idiopathic Pulmonary Fibrosis – Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016 35

Idiopathic Pulmonary Fibrosis – Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 36

Idiopathic Pulmonary Fibrosis – Pipeline by Apellis Pharmaceuticals Inc, H2 2016 37

Idiopathic Pulmonary Fibrosis – Pipeline by ARMO Biosciences, Inc., H2 2016 38

Idiopathic Pulmonary Fibrosis – Pipeline by Asahi Kasei Pharma Corp., H2 2016 39

Idiopathic Pulmonary Fibrosis – Pipeline by Biogen Inc, H2 2016 40

Idiopathic Pulmonary Fibrosis – Pipeline by Bioneer Corporation, H2 2016 41

Idiopathic Pulmonary Fibrosis – Pipeline by BiOrion Technologies B.V., H2 2016 42

Idiopathic Pulmonary Fibrosis – Pipeline by Bristol-Myers Squibb Company, H2 2016 43

Idiopathic Pulmonary Fibrosis – Pipeline by Celgene Corporation, H2 2016 44

Idiopathic Pulmonary Fibrosis – Pipeline by Chrysalis Pharma SAS, H2 2016 45

Idiopathic Pulmonary Fibrosis – Pipeline by Compugen Ltd., H2 2016 46

Idiopathic Pulmonary Fibrosis – Pipeline by Cynata Therapeutics Limited, H2 2016 47

Idiopathic Pulmonary Fibrosis – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 48

Idiopathic Pulmonary Fibrosis – Pipeline by FibroGen, Inc., H2 2016 49

Idiopathic Pulmonary Fibrosis – Pipeline by FibroStatin SL, H2 2016 50

Idiopathic Pulmonary Fibrosis – Pipeline by Galapagos NV, H2 2016 51

Idiopathic Pulmonary Fibrosis – Pipeline by GenKyoTex S.A., H2 2016 52

Idiopathic Pulmonary Fibrosis – Pipeline by GlaxoSmithKline Plc, H2 2016 53

Idiopathic Pulmonary Fibrosis – Pipeline by Global Blood Therapeutics, Inc., H2 2016 54

Idiopathic Pulmonary Fibrosis – Pipeline by GNI Group Ltd., H2 2016 55

Idiopathic Pulmonary Fibrosis – Pipeline by HEC Pharm Co., Ltd., H2 2016 56

Idiopathic Pulmonary Fibrosis – Pipeline by Histocell S.L., H2 2016 57

Idiopathic Pulmonary Fibrosis – Pipeline by iBio, Inc., H2 2016 58

Idiopathic Pulmonary Fibrosis – Pipeline by Immunomet Therapeutics, Inc. , H2 2016 59

Idiopathic Pulmonary Fibrosis – Pipeline by Inventiva, H2 2016 60

Idiopathic Pulmonary Fibrosis – Pipeline by Isarna Therapeutics GmbH, H2 2016 61

Idiopathic Pulmonary Fibrosis – Pipeline by Kadmon Corporation, LLC, H2 2016 62

Idiopathic Pulmonary Fibrosis – Pipeline by Kasiak Research Private Limited, H2 2016 63

Idiopathic Pulmonary Fibrosis – Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 64

Idiopathic Pulmonary Fibrosis – Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 65

Idiopathic Pulmonary Fibrosis – Pipeline by Lung Therapeutics Inc, H2 2016 66

Idiopathic Pulmonary Fibrosis – Pipeline by Moerae Matrix, Inc., H2 2016 67

Idiopathic Pulmonary Fibrosis – Pipeline by MorphoSys AG, H2 2016 68

Idiopathic Pulmonary Fibrosis – Pipeline by Novartis AG, H2 2016 69

Idiopathic Pulmonary Fibrosis – Pipeline by Nuevolution AB, H2 2016 70

Idiopathic Pulmonary Fibrosis – Pipeline by Pharmaxis Limited, H2 2016 71

Idiopathic Pulmonary Fibrosis – Pipeline by Promedior, Inc., H2 2016 72

Idiopathic Pulmonary Fibrosis – Pipeline by ProMetic Life Sciences Inc., H2 2016 73

Idiopathic Pulmonary Fibrosis – Pipeline by Pulmatrix, Inc., H2 2016 74

Idiopathic Pulmonary Fibrosis – Pipeline by Respira Therapeutics Inc, H2 2016 75

Idiopathic Pulmonary Fibrosis – Pipeline by Ribomic Inc., H2 2016 76

Idiopathic Pulmonary Fibrosis – Pipeline by Saje Pharma, LLC, H2 2016 77

Idiopathic Pulmonary Fibrosis – Pipeline by Samumed LLC, H2 2016 78

Idiopathic Pulmonary Fibrosis – Pipeline by Sanofi, H2 2016 79

Idiopathic Pulmonary Fibrosis – Pipeline by Sorrento Therapeutics, Inc., H2 2016 80

Idiopathic Pulmonary Fibrosis – Pipeline by SPR Biosciences LLC, H2 2016 81

Idiopathic Pulmonary Fibrosis – Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 82

Idiopathic Pulmonary Fibrosis – Pipeline by Therabron Therapeutics, Inc., H2 2016 83

Idiopathic Pulmonary Fibrosis – Pipeline by Vicore Pharma AB, H2 2016 84

Idiopathic Pulmonary Fibrosis – Pipeline by Yuhan Corporation, H2 2016 85

Assessment by Monotherapy Products, H2 2016 86

Number of Products by Stage and Target, H2 2016 88

Number of Products by Stage and Mechanism of Action, H2 2016 92

Number of Products by Stage and Route of Administration, H2 2016 96

Number of Products by Stage and Molecule Type, H2 2016 98

Idiopathic Pulmonary Fibrosis – Dormant Projects, H2 2016 247

Idiopathic Pulmonary Fibrosis – Dormant Projects (Contd..1), H2 2016 248

Idiopathic Pulmonary Fibrosis – Dormant Projects (Contd..2), H2 2016 249

Idiopathic Pulmonary Fibrosis – Dormant Projects (Contd..3), H2 2016 250

Idiopathic Pulmonary Fibrosis – Discontinued Products, H2 2016 251

List of Figures

List of Figures

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2016 18

Number of Products under Development for Idiopathic Pulmonary Fibrosis – Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Comparative Analysis by Clinical Stage Development, H2 2016 26

Comparative Analysis by Early Stage Products, H2 2016 27

Assessment by Monotherapy Products, H2 2016 86

Number of Products by Top 10 Targets, H2 2016 87

Number of Products by Stage and Top 10 Targets, H2 2016 87

Number of Products by Top 10 Mechanism of Actions, H2 2016 91

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 91

Number of Products by Routes of Administration, H2 2016 95

Number of Products by Stage and Routes of Administration, H2 2016 95

Number of Products by Top 10 Molecule Types, H2 2016 97

Number of Products by Stage and Top 10 Molecule Types, H2 2016 97

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports